Monopar Therapeutics
MNPR$452M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWILMETTE14 employees
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
MNPR News
Catalyst Timeline
1 upcoming, 0 past
EarningsNext
MNPR Earnings Report
Aug 11, 2026Confirmed
EPS Est: $-0.67 | FQ end 2026-06
How MNPR's past catalysts played out
Drug Pipeline
No drugs found in this phase.
📑
→Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
Catalyst Verdict
Full breakdown — the signals behind the verdict
Market-Implied Move
Regulatory Approvals
Frequently asked questions
When is Monopar Therapeutics's next FDA catalyst?→
Monopar Therapeutics's (MNPR) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MNPR biotech catalysts?→
Add MNPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Monopar Therapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply